The New York Times – America’s drug crisis now kills more people each day than car crashes or gun violence and has challenged the conventional wisdom about recovery. This week we’re discussing another idea whose time has past: trying to kick opioid addiction without medicines. That’s as smart as relying on willpower to overcome diabetes or asthma. Medicines greatly increase the chance of successfully kicking addiction and reduce the risk of death.
This author has yet to write their bio.Meanwhile lets just say that we are proud malford contributed a whooping 30 entries.
Entries by malford
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine use disorder, smoking cessation, and other addictions, today announced that EMB-001 met the primary endpoints of safety and tolerability in a Phase 1 clinical trial. Embera also announced that the Company’s Chief Executive Officer, Robert Linke and Chief Medical Officer, Dr. Michael Detke, will present at the Biotech Showcase on Monday, January 11, 2016 at 2:30pm in San Francisco, California.
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation, cocaine use disorder and other addictions, today announced the first subject received the initial dose in a Phase 1 clinical trial evaluating EMB-001. A novel combination of the FDA-approved drugs metyrapone and oxazepam, EMB-001 is being investigated for the potential treatment of cocaine use disorder and other addictions such as tobacco and methamphetamine use disorders.
Embera NeuroTherapeutics, Inc., a specialty biopharmaceutical company developing novel treatments for smoking cessation, cocaine use disorder and other addictions, today announced that it raised $1.9 million in Series A-2 financing. The funding enables the Company to complete a Phase 1, combined single and multiple rising dose clinical trial evaluating the safety and pharmacokinetics of EMB-001 in volunteers who smoke cigarettes but are otherwise healthy.
Listen to the 2/18/14 episode of BioTech Nation with host Dr. Moira Gunn. Robert Linke, Embera’s CEO, discusses EMB-001 and smoking cessation.
National Institute on Drug Abuse – Tobacco use kills approximately 440,000 Americans each year, with one in every five U.S. deaths the result of smoking. Smoking harms nearly every organ in the body, causes many diseases, and compromises smokers’ health in general. Nicotine, a component of tobacco, is the primary reason that tobacco is addictive.
Embera NeuroTherapeutics Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation and other addictions, announced today the publication of results from a preclinical study of the combination use of metyrapone and oxazepam to treat nicotine addictions. Metyrapone and oxazepam, both of which are FDA-approved drugs, comprise EMB-001, Embera’s lead pipeline candidate. Researchers found that at the lowest doses tested, the combination more effectively reduced nicotine intake than did either drug alone.
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation and other addictions, announced today that it has closed on $4.5 million in a continuation of its Series A financing. Embera’s existing venture investors, Louisiana Ventures, L.P., Louisiana Fund I, and Themelios Ventures, as well as private investors, participated in the round. Proceeds from this financing, combined with development grant funding from the National Institute for Drug Abuse, will support clinical development of EMB-001 through a Phase 1 safety study, enabling Embera’s clinical development programs for both smoking cessation and cocaine dependence.
Addictive behaviors – from tobacco use to eating disorders – are among the most difficult to treat and the least likely to result in permanent recovery. That’s precisely why Embera NeuroTherapeutics Inc. is excited about prospects for its EMB-001 . Rather than seeking to block the effects of an addictive substance or substitute a safer compound, the firm’s drug combination suppresses the craving that drives addiction.
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for addiction and obesity, announced today that the Louisiana State University Health Sciences Center (LSUHSC-S) has received a $3.9 million dollar grant from the National Institute on Drug Abuse (NIDA). The grant will support the next stages of development for Embera’s drug candidate EMB-001 to treat cocaine dependence, as well as advance EMB-001 into clinical testing. Work done under this grant will also support Embera’s clinical development program for EMB-001 for smoking cessation.